Apical Sodium-Dependent Bile Acid Transporter

ASBT; Ileal Bile Acid Transporter; IBAT; SLC10A2

Apical sodium-dependent bile acid transporter (ASBT, also known as IBAT-ileal bile acid transporter, SLC10A2) an ileal Na⁺-dependent transporter, actively reabsorbs bile acids (BAs) from the gut lumen. Bile acids are synthesized in the liver, stored in the gallbladder, and secreted into the duodenum at meals. ASBT is found on the brush border/apical membrane of ileal enterocytes, as well as the apical surface of renal tubules and cholangiocytes. Conjugated bile acids are actively transported by IBAT from the lumen/ apical side into the interior of the enterocyte and exported via the basolateral membrane organic solute transporter α/β heterodimer (OSTα/β; encoded by SLC51A/B) into the portal circulation, which allows for return of bile acids back to the liver. This process is a critical step in the enterohepatic circulation (EHC) of BAs and plays important roles in the homeostasis of BAs in the body. Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. In addition, ASBT is also a popular delivery target for developing prodrugs, due to its intestinal localization, high expression and high uptake capacity.

Apical Sodium-Dependent Bile Acid Transporter Inhibitors (9)

Apical Sodium-Dependent Bile Acid Transporter Related Products (15):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-109120

Odevixibat	Inhibitor	99.92%
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.

HY-16643

Linerixibat		99.88%
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.

HY-15790

Elobixibat	Inhibitor	99.91%
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC₅₀ value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.

HY-16747

Maralixibat chloride	Inhibitor	99.08%
Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.

HY-129982

SC-435		98.73%
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-168523

S1647	Inhibitor
S1647 is a ASBT and SOAT dual inhibitor. S1647 can be used in the study of intrahepatic cholestasis, cholestatic pruritus, and obstipation.

HY-15790A

Elobixibat hydrate		99.44%
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research.

HY-101190

Volixibat
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH).

HY-148795

Ritivixibat	Inhibitor
Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

HY-109120S

Odevixibat-d₅	Inhibitor
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.

HY-19298

S-8921
S-8921 is an ileal Na⁺/bile acid cotransporter (IBAT) inhibitor.

HY-15790H

(S)-Elobixibat	Inhibitor	98.75%
(S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.

HY-109120S1

Odevixibat-¹³C₆	Inhibitor
Odevixibat-¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.

HY-19264

264W94
264W94 is a potent ileal bile acid transporter (IBAT) inhibitor and a new cholesterol lowering agent. 264W94 has CYP7A1 induction, and antilipemic action.

HY-15790R

Elobixibat (Standard)	Inhibitor
Elobixibat (Standard) is the analytical standard of Elobixibat. This product is intended for research and analytical applications. Elobixibat is a potent ileal bile acid transporter (IBAT) inhibitor with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.

Name
Email *

	Sorry, but the email address you supplied was invalid.